Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward- looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 ... $6 million in Series B funding and secured Otter ... and investment capital will accelerate commercialization of GGI’s Agriplier™ ... multiple crop types. , “Since our first meeting, ... commitment to the biological product space,” said Alan Sobba, ...
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , ... patient safety, today announced the appointment of Mary ... With 28 years of experience preparing companies for ... 2013 as Executive Vice President of Corporate Development and ... performance improvement business , as well as corporate strategy ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... , ... Services, Inc. Is Pleased To Announce The Launch Of Its New And Improved Website. ... A More User-Friendly Design Layout To Enhance Functionality And Navigation. The Site Also Offers ... Sciences And Lab Operations. , ...
... , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 ... log on to the web at the, ...
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), a ... products for the treatment of cancer, today announced that ... end 2009 financial results on Wednesday, August 12, 2009 ... Following the release, Oncothyreon,s management expects to discuss these ...
Cached Biology Technology:One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
(Date:8/28/2014)... Athens, Ga. The support of peer groups ... effective breastfeeding programs, according to recent University of ... mothers in the Athens-Clarke County area determined that ... the outcomes of mothers of infants. , "Mothers ... be successful at breastfeeding," said study co-author Alex ...
(Date:8/28/2014)... Advocate and Senior Staff Attorney at the Electronic Frontier ... of biometric and mobile commerce experts set to speak ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe de ... this year,s event is Mobility at the Crossroads of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... NEW YORK (Feb. 29, 2012)Exposure to lead wreaks havoc ... and reduced potential for learning. But the precise mechanism ... has largely remained unknown. New research led by ... of Environmental Health Sciences at Columbia University Mailman School ...
... New Orleans, LA Research led by Nicolas Bazan, MD, ... Excellence at LSU Health Sciences Center New Orleans, has found ... of experimental stroke. Dr. Bazan was issued a patent on ... crosses the blood-brain barrier. The findings are published in the ...
... of global scientists, led by researchers at Intermountain Medical Center ... accurate way to administer warfarin, one of the most commonly ... As part of a worldwide study, the research team ... data with a mathematical model to help physicians more accurately ...
Cached Biology News:In what ways does lead damage the brain? 2LSUSHC research identifies new experimental drug for stroke 2Researchers find safer way to use common but potentially dangerous medication 2Researchers find safer way to use common but potentially dangerous medication 3
... The H2OBIT is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. ,A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
Biology Products: